Hutchison China Meditech Ltd., of London, said it completed patient enrollment in the phase III FRESCO trial of fruquintinib (HMPL-013) in third-line locally advanced or metastatic colorectal cancer in China. The pivotal study is enrolling patients who have failed at least two prior systemic antineoplastic therapies, and the primary endpoint is overall survival.